According to a local exec, good times are ahead for Glaxo's vaccines unit in India--and the company's recent pickup of Novartis' non-flu vaccine assets will help it get there.
The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top.
The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.
As rates of drug-resistant tuberculosis rise across the globe, GlaxoSmithKline is partnering with Switzerland's BioVersys and France's University of Lille to develop a preclinical candidate against the airborne disease.
Ever since China began investigating GlaxoSmithKline's business practices last year, analysts have feared the British drug giant could get in big trouble in its home country, too. Their worries appear to be justified as Britain's Serious Fraud Office said today it had opened a criminal investigation.
As China steps up its investigations into alleged corruption at GlaxoSmithKline and other multinational pharmaceutical companies, China-based healthcare companies are also taking a major hit.
The country is in the midst of a full-blown corruption investigation aimed largely at Big Pharma, and now it has picked another target: Swiss drugmaker Roche.
GlaxoSmithKline has been a partner of the GAVI Alliance for years, offering some of its vaccines at low cost to help support immunization efforts for children in emerging countries. But now, it's going one step further with a 5-year price freeze on three of its vaccines for countries that graduate from GAVI funding.
GlaxoSmithKline has missed out on a big new market for its blood cancer drug Arzerra. Approved to treat chronic lymphocytic leukemia, Arzerra (ofatumumab) failed to pass the test in a B-cell lymphoma trial. And now, Glaxo officials say they're giving up on the indication.
Pharma industry probes are far from over, China-based professionals say. And with the country trying desperately to drive down healthcare costs for its population of close to 1.4 billion, Big Pharma had best be careful. Local officials are making it clear that Big Brother is watching.